Shareholders vote June 8 to accept Roche's $2.1 bil. offer for 60% of the biotech firm. The transaction will become effective after a 20-day waiting period and approval by the Federal Trade Commission, which asked for more information on the proposed deal on March 23. Genentech said both companies are "currently working to satisfy the FTC's request".
You may also be interested in...
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.